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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effectiveness and safety of pharmacotherapies as compared with each other, placebo or no pharmacotherapy (supportive
care) for reducing cannabis withdrawal and promoting cessation.
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B A C K G R O U N D
Description of the condition
Cannabis is the world’s most widely produced, seized and con-
sumed illicit drug (World Drug Report 2010).
The main active compound in all cannabis products is 19 - tetrahy-
drocannabinol (THC) (EMCDDA Cannabis Drug Profile). The
number of cannabis users globally is estimated to range from
between 129 to 191 million people or 2.9% to 4.3% of the
world’s population (World Drug Report 2010). Prevalence rates of
cannabis use vary widely between regions, with the highest preva-
lence rates in Oceania, North America and sub-regions of Africa
(World Drug Report 2010). Levels of cannabis use in Europe have
generally stabilized, however rates of use are still increasing in some
European countries (World Drug Report 2010). Cannabis use has
declined in Oceania (World Drug Report 2010). In contrast, lev-
els of cannabis use in South America, Africa and Asia appear to
be rising (World Drug Report 2010). Cannabis use also appears
to be increasing in the United States (SAMHSA 2010) although
cannabis use in North America as a whole appears to be stabilizing
or decreasing (World Drug Report 2010). Cannabis use within
some indigenous communities in North America and Australia
also appears to be more prevalent than their non-indigenous coun-
terparts (Beauvais 2004, Clough 2004).
Cannabis use causes significant adverse effects (Budney 2007).
Probable harmful consequences of cannabis use include cardio-
vascular disease, impaired respiratory function and an increased
risk of involvement in motor vehicle accidents (Hall 2009). The
use of cannabis has consistently been found to be associated with
psychotic symptoms (Minozzi 2010).Intense long-term cannabis
use has also been associated with impaired memory function, and
these deficits are greater with the earlier age of initiation to cannabis
use, and increased frequency, duration and dose of cannabis use
(Solowij 2008). Memory deficits also appear to persist beyond the
period of acute intoxication (Solowij 2008). Heavy users also re-
port significantly lower levels of quality of life in terms of their
physical and psychological health, the quality of their interpersonal
relationships and work satisfaction (Gruber 2003). Cannabis use
may also lead to dependence (Budney 2007). It has been estimated
that some 10% of those who have used cannabis at least once, will
develop cannabis dependence (Wagner 2002).
As with other drugs of dependence, the risk of developing depen-
dency is influenced by multiple factors. However it is likely that
intensive use of cannabis, that is daily or near daily use, is likely
to increase the risk of cannabis dependence (EMCDDA 2004).
It has been suggested that the earlier initiation of cannabis use,
increased use of more potent forms of cannabis (e.g. the flowering
heads of the female cannabis plant) and the greater use of water-
pipes may have led to an increased amount of THC consump-
tion by some cannabis users and therefore possibly greater rates of
cannabis dependence (Hall 2001).
Estimates of the numbers of cannabis users experiencing with-
drawal are variable (Agrawal 2008) (Hasin 2008) (Copersino
2006) (Chung 2008) (Cornelius 2008) (Budney 2006). Factors
influencing the severity of cannabis withdrawal are yet to be iden-
tified, however it seems likely that the greater the intensity and
duration of use, the greater the prevalence and severity of cannabis
withdrawal symptoms, especially among those seeking treatment
for cannabis dependence. More intensive cannabis users may there-
fore be more likely to experience withdrawal symptoms when the
use of the drug is abruptly terminated, and they may therefore
require assistance with the withdrawal and cessation process.
Support for a specific cannabis withdrawal syndrome has increased
recently with the proposed inclusion of a cannabis withdrawal
disorder in DSM-V (DSM-V). The signs and symptoms of the
cannabis withdrawal syndrome include irritability, anger or in-
creased aggression, nervousness or anxiety, sleep difficulty (in-
somnia), decreased appetite or weight loss, restlessness, depressed
mood, and at least one of the following physical symptoms causing
significant discomfort such as stomach pain, shakiness/tremors,
sweating, fever, chills or headache (DSM-V). Symptoms of the
cannabis withdrawal syndrome begin following cessation of heavy
or prolonged cannabis use. Onset of symptoms is usually within
24 to 48 hours of abstinence, reaching peak intensity within the
first week (Budney 2007). Symptoms may persist for up 3 to 4
weeks (Milin 2008), although there appears to be significant in-
dividual variability. The cannabis withdrawal syndrome is not life
threatening nor is it associated with significant medical or psychi-
atric consequences (Budney 2003).
Demand for treatment for cannabis related disorders has generally
increased worldwide over the past decade, albeit with significant
regional variation. The World Drug Report gives data on treatment
demand in terms of the proportion of treatment services provided
for the major drugs of dependence. Cannabis related disorders
have dominated demand for drug treatment in Africa over the
past 10 years with treatment rates consistently over 60%. Demand
for cannabis treatment has grown significantly in some regions,
more than doubling in Europe and South America, and more than
trebling in Oceania (World Drug Report 2010). North America
as a whole was the only region to see a decrease in the contribution
of cannabis to treatment demand (World Drug Report 2010), but
within the United States, cannabis admissions increased by 32%
between 1996 and 2006 (SAMHSA 2008).
Description of the intervention
There are currently no accepted pharmacotherapies for the treat-
ment of cannabis withdrawal or cessation (Nordstrom 2007). The
identification and development of medications to fill this gap has
become an increasing priority among researchers (Vandrey 2009).
However a number of pharmacotherapies have been proposed as
possible experimental interventions to attenuate the symptoms
and signs of cannabis withdrawal and promote cessation.
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These medications fall into two broad groups. The first group
are medications that affect cannabinoid receptor systems includ-
ing agonist (e.g. preparations of THC), and antagonist medica-
tion (e.g. rimonabant). The second group are medications that
affect the specific symptoms of cannabis withdrawal. This group
includes medications that have previously been used in the treat-
ment of other drug withdrawal syndromes (e.g. bupropion), as
well as medications that are known to alleviate specific withdrawal
symptoms such as irritability, anxiety or sleep difficulty (e.g. ben-
zodiazepines).
How the intervention might work
The proposed pharmacologic interventions may potentially lessen
the symptoms and signs of cannabis withdrawal. The availabil-
ity of effective pharmacotherapy for cannabis withdrawal may en-
courage people who are cannabis dependent to enter treatment,
and may increase the rates of completion of withdrawal, cessation
of cannabis use and entry into relapse prevention treatment.
It has been reported that the experience of cannabis withdrawal
symptoms may be a significant obstacle to achieving abstinence in
cannabis dependent individuals ( Budney 2006; Copeland 2001;
Hart 2005). Therefore the effective treatment of the cannabis with-
drawal syndrome is an important component of cessation and the
first step in the establishment of abstinence.
Why it is important to do this review
As discussed above, there is increasing recognition that cannabis
use and dependence is an important public health issue.
Not all cannabis users will need pharmacotherapies to manage
withdrawal or support cessation of their use. However it is impor-
tant that effective pharmacotherapies are identified for the treat-
ment of cannabis withdrawal, especially in intensive cannabis users
who describe withdrawal symptoms on cessation.
Three reviews have previously been undertaken in the area of
pharmacotherapies for cannabis use disorders (Benyamina 2008;
Nordstrom 2007; Vandrey 2009). However none of these are sys-
tematic reviews and they do not focus specifically on treatments
for cannabis withdrawal and cessation.
No Cochrane review to date examines the effectiveness of phar-
macotherapies for the treatment of cannabis withdrawal. This re-
view will contribute to the establishment of best practice in the
management of cannabis withdrawal and cessation.
O B J E C T I V E S
To assess the effectiveness and safety of pharmacotherapies as com-
pared with each other, placebo or no pharmacotherapy (supportive
care) for reducing cannabis withdrawal and promoting cessation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised and quasi-randomised controlled trials examining
pharmacological interventions for cannabis withdrawal will be in-
cluded. These studies will have to provide detailed information on
the type and dose of intervention medication used and the charac-
teristics of patients treated. Studies will also be required to provide
information on the nature and severity of withdrawal symptoms
and signs experienced, the occurrence of adverse effects and the
rates of completion of the scheduled intervention.
Types of participants
We will include studies that involve participants who are diagnosed
according to DSM-IV or ICD-10 criteria as cannabis dependent
or where dependence is likely based on reported dose, duration
and frequency of use (daily or multiple days per week).
Studies involving participants dependent on, and withdrawing
from, both cannabis and nicotine will be included. Subgroup anal-
yses will be used to assess the impact of concurrent nicotine and
cannabis withdrawal on the effectiveness of pharmacotherapies
for cannabis withdrawal. Studies involving concurrent withdrawal
from substances other than nicotine will be excluded.
Studies involving managed cannabis withdrawal within either an
inpatient or outpatient setting will be included.
Types of interventions
Experimental interventions will involve the administration of
medications with the aim of reducing the symptoms and signs of
cannabis withdrawal or promoting cessation of cannabis use.
Comparison: Different pharmacotherapies, placebo or no phar-
macotherapy (supportive care).
Types of outcome measures
Primary outcomes
1. Intensity of withdrawal; as measured via the use of visual
analogue scales, peak withdrawal scores, the need for
symptomatic medications in addition to the experimental
intervention, and clinician and participant assessments of
withdrawal.
2. Nature, incidence and frequency of adverse effects and
whether the planned medication regime was modified in
response to adverse effects.
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3. Completion of withdrawal treatment; number of people
who complete withdrawal treatment and the portion of the
scheduled treatment episode that is completed on average.
4. Number of participants abstinent from cannabis at the end
of treatment as determined by self-report and /or urine drug
screens.
Secondary outcomes
1. Number of participants engaged in further treatment
following completion of the withdrawal intervention. As
discussed in the Background section, treatment of the cannabis
withdrawal period may be considered as the first step in
treatment, therefore engagement in further relapse prevention
treatment may be considered to be a valid outcome of interest.
2. Level of cannabis use at the end of treatment; as measured
via participant reported level of use and / or urine drug screens.
Search methods for identification of studies
All searches will include non-English language literature. We will
assess studies with English abstracts on the basis of the abstract. If
it is thought that the study is likely to meet inclusion criteria, it
will be translated sufficiently to extract study methods and results.
Electronic searches
We will search:
1. Cochrane Central Register of Controlled Trials (The
Cochrane Library, issue 10 2010) which includes the Cochrane
Drugs and Alcohol Group’ Register of Trials, via OVID Online
2. MEDLINE (1950 to Present with Daily Update) via Ovid
Online
3. EMBASE (1980 to 2010 Week 28) via Ovid Online
4. PsycINFO (to 26 July 2010) via EBSCO Host
We developed a search strategy to retrieve references relating to the
pharmacologic treatment of cannabis withdrawal. This strategy
was adapted to each of the databases listed above.
For details see Appendix 1; Appendix 2; Appendix 3; Appendix 4.
We will also search some of the main electronic sources of ongoing
trials:
• Current Controlled Trials (http://www.controlled-
trials.com/)
• Clinical Trials.gov




We will check the reference lists of all relevant review articles and
retrieved studies to identify any further studies of interest that were
not retrieved by the electronic search. We will also contact selected
researchers who are active in the area, seeking information about
unpublished study reports. We will check conference proceedings
likely to contain trials relevant to the review.
Data collection and analysis
Selection of studies
Two authors (KM and LG) will independently assess the titles and
abstracts of records retrieved from the systematic search. Each au-
thor will assess potentially relevant studies for eligibility according
to pre-defined inclusion and exclusion criteria. All authors agreed
on the inclusion and exclusion criteria. The final selection of stud-
ies into the review will be undertaken by two authors. Disagree-
ments about whether a study should be included or not will be
resolved by discussion, or by referral to a third party if necessary
(RA). No attempt will be made to blind the authors to the names
of the study authors, institutions, journal of publication and re-
sults when eligibility criteria are applied.
Data extraction and management
Two authors (KM and LG) will independently extract data from
the published reports using a data collection form. Disagreements
will be resolved by discussion or by arbitration by a third party.
Key findings of studies will be summarized descriptively in the first
instance and the capacity for quantitative meta-analysis will be
considered. We will contact study authors if we require additional
information to include studies in meta-analyses.
Assessment of risk of bias in included studies
The Cochrane Handbook for Systematic Reviews of Interventions
(Version 5.0.2 updated September 2009) recommends the use of
a two-part tool to assess the risk of bias in studies included in
Cochrane reviews. This tool addresses the specific domains of se-
quence generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting and ‘other issues’.
Each included study will be analysed and described according to
these domains and a judgement of the likelihood of bias will be
provided. A judgement of ‘Yes’ indicates low risk of bias, ‘No’ indi-
cates high risk of bias and ‘Unclear’ indicates an unknown or un-
clear risk of bias. An assessment of the risk of bias for each eligible
study will be included in the ‘Characteristics of Included Studies’
section. See Appendix 5 for the detailed description of the criteria
used.
Measures of treatment effect
Where possible, the treatment effect for each dichotomous out-
come will be expressed as a relative risk (RR) with 95% confidence
intervals (CI). Where there is a comparable outcome measure (e.g.
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time in treatment) the treatment effect for each continuous out-
come will be expressed as a mean difference (MD) with 95% CIs.
Where there is variability in outcome measure (e.g. withdrawal as-
sessment scales) the treatment effect for each continuous outcome
will be expressed as a standardized mean difference (SMD) with
95% CIs.
Unit of analysis issues
If there are trials with multiple treatment arms that may be in-
cluded in a meta-analysis, then we will either combine groups to
allow single-pair wise comparisons or we will set up separate anal-
yses or perform subgroup analyses and suppress the calculation of
overall totals to avoid the unit of analysis error of double-counting
participants. Also if Urine Drug Screens are reported in studies,
then the unit of analysis will be the number of study participants
not the number of tests performed.
Dealing with missing data
When possible, attempts will be made to contact the original in-
vestigators to request missing data. If sufficient studies meet the
inclusion criteria, a sensitivity analysis may be performed to assess
the impact of different approaches to handling missing data. In
addition the potential impact of missing data on review findings
will be addressed in the discussion section.
Assessment of heterogeneity
Clinical and methodological heterogeneity will be assessed by re-
viewing the variations between studies in terms of the character-
istics of participants included, the interventions and the reported
outcomes. Meta-analysis will only be undertaken if sufficient stud-
ies are located that are clinically and methodologically suitable to
combine.
In order to identify heterogeneity, results will be inspected graph-
ically in the first instance. Where there is statistical heterogeneity
as indicated by a Chi-squared test (p-value <0.05) or an I-squared
statistic of at least 50%, then a random effects model will be used
for meta-analyses.
Assessment of reporting biases
If a meta-analysis is conducted, funnel plots (plots of the effect
estimate from each study against the standard error) will be used
to assess the potential for bias related to the size of the trials, which
could indicate possible publication bias.
Data synthesis
Statistical analysis will be undertaken using Review Manager 5.
Dichotomous data (e.g. number completing treatment) will be
used to calculate relative risks. For continuous data (e.g. with-
drawal scores) either mean differences or standardized mean dif-
ferences will be calculated. If significant statistical heterogeneity is
detected, then a random effects model will be applied.
Subgroup analysis and investigation of heterogeneity
This review will consider the following potential sources of het-
erogeneity through subgroup analyses:
1. Patterns of cannabis use and the estimated level of THC
intake (as indicated by duration and level of use, number of days
of use, number of uses per day [frequency], modality of use /
route of administration, age of initiation of use)
2. Concurrent tobacco smoking
3. Concurrent psychiatric illness +/- current treatment for a
psychiatric illness
4. The nature of the treatment setting
5. The nature of adjunct treatment
Sensitivity analysis
Methodological quality will not be used as a criterion for inclusion
in this review. We intend to perform a sensitivity analysis to judge
methodological quality. If differences in results are present among
studies at different risks of bias, then a sensitivity analysis will be
undertaken. Studies with a higher risk of bias will be excluded
from analysis at this stage.
A C K N O W L E D G E M E N T S
None
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A P P E N D I C E S
Appendix 1. CENTRAL Search strategy via OVID online
1. exp Cannabis/
2. cannabis.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
3. mari#uana.mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
4. exp Marijuana abuse
5. exp Substance Withdrawal Syndrome/
6. exp Metabolic Detoxication, Drug/
7. (detoxifi$ or desintoxi$ or disintoxi$ or disintossi$ or withdrawal).mp. [mp=title, original title, abstract, mesh headings, heading
words, keyword]
8. 1 or 2 or 3 or 4
9. 5 or 6 or 7
10. 8 and 9
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Appendix 2. MEDLINE Search Strategy via Ovid Online
1. (cannabis or mari#uana).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
2. exp Cannabis/
3. exp Marijuana Abuse/
4. withdrawal.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
5. exp Substance Withdrawal Syndrome/
6. (detoxifi$ or desintoxi$ or disintoxi$ or disintossi$).mp. [mp=title, original title, abstract, name of substance word, subject
heading word, unique identifier]
7. exp Metabolic Detoxication, Drug/
8. 1 or 2 or 3
9. 4 or 5 or 6 or 7
10. 8 and 9
11. limit 10 to human
Appendix 3. EMBASE Search Strategy via Ovid Online
1. cannabis.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
2. mari#uana.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
3. *cannabis/
4. *cannabis addiction/ or *cannabis smoking/
5. *drug withdrawal/ or *withdrawal syndrome/
6. *drug detoxification/ or *detoxification/
7. (detoxifi$ or desintoxi$ or disintoxi$ or disintossi$).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
8. 1 or 2 or 3 or 4
9. 5 or 6 or 7
10. 8 and 9
11. limit 10 to human





5. MM “Marijuana Usage”
6. MM “Drug Withdrawal”
7. MM “Detoxification”
8. detoxification or detoxify or detoxified
9. S1 or S2 or S3 or S4 or S5
10. S6 or S7 or S8
11. S9 and S10
12. limit 11 to human
8Pharmacotherapies for cannabis withdrawal (Protocol)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 5. Criteria for risk of bias assessment in RCTs and CCTs
Item Judgment Description
1 Was the method of randomization ade-
quate?
Yes The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimization
No The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability
of the intervention
Unclear Insufficient information about the sequence generation process to per-
mit judgement of Yes or No
2 Was the treatment allocation concealed? Yes Investigators enrolling participants could not foresee assignment be-
cause one of the following, or an equivalent method, was used to con-
ceal allocation: central allocation (including telephone, web-based, and
pharmacy-controlled, randomization); sequentially numbered drug
containers of identical appearance; sequentially numbered, opaque,
sealed envelopes
No Investigators enrolling participants could possibly foresee assignments
because one of the following method was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or non opaque
or not sequentially numbered); alternation or rotation; date of birth;
case record number; any other explicitly unconcealed procedure
Unclear Insufficient information to permit judgement of Yes or No. This is
usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3 Was knowledge of the allocated inter-
ventions adequately prevented during the
study? (blinding of patients, provider,
outcome assessor)
Objective outcomes
Yes Blinding of participants, providers and outcome assessor and unlikely
that the blinding could have been broken;
Either participants or providers were not blinded, but outcome assess-
ment was blinded and the non-blinding of others unlikely to introduce
bias
No blinding, but the objective outcome measurement are not likely
to be influenced by lack of blinding
No No blinding or incomplete blinding, and the outcome or outcome
measurement is likely to be influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken;
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Either participants or outcome assessor were not blinded, and the non-
blinding of others likely to introduce bias
Unclear Insufficient information to permit judgement of Yes or No;
4 Was knowledge of the allocated inter-
ventions adequately prevented during the
study? (blinding of patients, provider,
outcome assessor)
Subjective outcomes
Yes Blinding of participants, providers and outcome assessor and unlikely
that the blinding could have been broken;
Either participants or providers were not blinded, but outcome assess-
ment was blinded and the non-blinding of others unlikely to introduce
bias
No No blinding or incomplete blinding, and the outcome or outcome
measurement is likely to be influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken;
Either participants or outcome assessor were not blinded, and the non-
blinding of others likely to introduce bias
Unclear Insufficient information to permit judgement of Yes or No;
5 Were incomplete outcome data ade-
quately addressed?
For all outcomes except retention in treat-
ment or drop out
Yes No missing outcome data;
Reasons for missing outcome data unlikely to be related to true out-
come (for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a clinically
relevant impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardized difference in means) among missing outcomes not
enough to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods
All randomized patients are reported/analyzed in the group they were
allocated to by randomization irrespective of non-compliance and co-
interventions (intention to treat)
No Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardized difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size;
As-treated analysis done with substantial departure of the intervention
received from that assigned at randomization;
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Unclear Insufficient reporting of attrition/exclusions to permit judgement of
Yes or No (e.g. number randomized not stated, no reasons for missing
data provided; number of drop out not reported for each group);
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